BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW), a technology-driven drug development company leveraging artificial intelligence (AI) and machine learning, has officially entered the commercial phase of its collaboration with Sygnature Discovery, a leading contract research organization (CRO) specializing in drug discovery. The partnership's flagship product, BullFrog Data Networks(TM), is now being introduced to Sygnature's global biopharma client base, marking a significant milestone for both companies.
The commercial rollout, which began on September 12, follows the successful training of Sygnature's global business development team. This initiative equips Sygnature's representatives to market BullFrog Data Networks(TM) as part of their comprehensive portfolio of drug discovery solutions. The collaboration is projected to generate $15-$30 million in revenue by 2028, underscoring its potential to transform the biopharma landscape.
Vin Singh, Founder and CEO of BullFrog AI, emphasized the significance of this milestone:
"The official kickoff of sales through Sygnature marks a potential inflection point for BullFrog AI. We are now positioned to realize the revenue potential of this collaboration and deliver our AI-driven data insights platform to biopharma innovators globally. Our shared commitment to accelerating drug discovery will create significant value for researchers and patients alike."
BullFrog Data Networks(TM) is designed to empower researchers by enabling them to navigate complex, multi-modal datasets and uncover critical insights into disease biology. The platform's applications span early target identification, mechanism-of-action elucidation, patient stratification, drug repurposing, and clinical trial optimization. Its intuitive, disease-centric interface provides a visual and user-friendly experience, making it a powerful tool for biopharma researchers.
Stuart Onions, Chief Technical Officer at Sygnature Discovery, shared his enthusiasm for the platform:
"Our team is excited to offer BullFrog Data Networks to our clients. The platform strengthens our ability to deliver best-in-class solutions, enabling biopharma researchers to unlock the full potential of their data and improve R&D efficiency."
About BullFrog AI
BullFrog AI is at the forefront of using AI and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, the company employs causal AI and its proprietary bfLEAP(TM) platform to analyze complex biological data. This approach aims to streamline therapeutic development and reduce failure rates in clinical trials. For more information, visit BullFrog AI.
About Sygnature Discovery
Sygnature Discovery is a globally recognized integrated drug discovery CRO headquartered in Nottingham, UK, with additional sites in Alderley Park, Macclesfield, Glasgow, Montreal, and Quebec City. With a team of over 1,000 employees, including 900 scientists, Sygnature partners with biotech, pharma, and nonprofit organizations worldwide. Since 2011, the company has delivered 56 novel pre-clinical and 35 clinical compounds, with its scientists named on over 235 patents. Sygnature specializes in therapeutic areas such as oncology, inflammation, immunology, neuroscience, metabolic diseases, infectious diseases, and fibrotic diseases.
